Search

Your search keyword '"Portieri M"' showing total 2 results
Start Over Author "Portieri M" Topic 03 medical and health sciences
2 results on '"Portieri M"'

1. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

Author

Ruberto, F., Chistolini, A., Curreli, M., Frati, G., Marullo, A. G. M., Biondi-Zoccai, G., Mancone, M., Sciarretta, S., Miraldi, F., Alessandri, F., Ceccarelli, G., Barone, F., Santoro, C., Alvaro, D., Pugliese, F., Pulcinelli, F. M., Albante, A., Antonelli, G., Araimo-Morselli, F., Auricchio, D., Bilotta, F., Brisciani, G. B. -Z. M., Bruno, K., Cappannoli, A., Cardinale, V., Celli, P., Consolo, S., Croce, C., Crocitti, B., D'Ettorre, G., De Daniela, L., De Lazzaro, F., Fedele, F., Galardo, G., Giannetti, L., Ianni, S., Imperiale, C., Maestrini, V., Magnanimi, E., Maldarelli, F., Martelli, S., Mastroianni, C., Messina, T., Pattelli, E., Pecorari, F., Perrella, S., Piazzolla, M., Portieri, M., Ratini, F., Ricci, C., Santopietro, Pietro, Tellan, G., Titi, L., Tordiglione, P., Tosi, A., and Trigilia, F.

Subjects
Male, Platelet Aggregation, vonWillebrand factor, 030204 cardiovascular system & hematology, Platelet membrane glycoprotein, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Platelet, 030212 general & internal medicine, Aged, 80 and over, biology, Hematology, Middle Aged, Host-Pathogen Interactions, Female, Arachidonic acid, Cardiology and Cardiovascular Medicine, Protein Binding, circulatory and respiratory physiology, Adult, Blood Platelets, Platelets, Agglutination, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Platelet Function Tests, Article, Von Willebrand factor, reduced platelet aggregation, agglutination, COVID‑19, 03 medical and health sciences, Antigen, Von Willebrand factor, Internal medicine, von Willebrand Factor, medicine, Humans, Platelet activation, Ristocetin, Aged, SARS-CoV-2, business.industry, COVID-19, Thrombosis, Covid 19, Agglutination (biology), Endocrinology, chemistry, biology.protein, business
Abstract

Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients. Electronic Supplementary Material The online version of this article (10.1007/s11239-020-02339-6) contains supplementary material, which is available to authorized users.

Published
2021
Full Text
View/download PDF

2. Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19):relationship with mortality

Author

Violi, F., Ceccarelli, G., Cangemi, R., Cipollone, F., D'Ardes, D., Oliva, A., Pirro, M., Rocco, M., Alessandri, F., D'Ettorre, G., Lichtner, M., Pignatelli, P., Ferro, D., Ruberto, F., Lip, G. Y. H., Pugliese, F., Mastroianni, C. M., Albante, A., Auricchio, D., De Lazzaro, F., M. De Lauri D., Di Santo, C., Ianni, S., Magnanimi, E., Ratini, F., Sabani, A., Titi, L., Vaccaro, P., Giordano, G., Manganelli, C., Mancone, M., Bruno, K., Celli, P., Consolo, S., Croce, C., Giannetti, L., Martelli, S., Messina, T., Pattelli, E., Perrella, S., Portieri, M., Ricci, C., Almenrader, N., Arzilla, R., Delia, E., Di Giovanni, C., Laderchi, A., Macri, C., Marandola, M., Nardecchia, G., Pacilli, M., Pacini, F., Araimo Morselli, F., Imperiale, C., Tordiglione, P., Ciardi, M. R., Ajassa, C., D'Agostino, C., Russo, G., Trinchieri, V., Guariglia, P., Antonelli, L., Cuomo, R. M., Carnevalini, M., Mastropietro, C., Iaiani, G., Mezzaroma, I., Falciano, M., Brogi, A., Celani, L., Cavallari, N. E., Rivano Capparuccia, M., Massetti, A. P., Fimiani, C., Santori, M., Bianchi, A., Franchi, C., De Angelis, M., Sereno, S., Furlan, C., De Sanctis, G., Paoletti, F., Pasculli, P., Cogliati Dezza, F., Vassalini, P., Cancelli, F., De Girolamo, G., Savelloni, G., Valeri, S., Siccardi, G., Alessi, F., Recchia, G., Ridolfi, M., Romani, F. E., Aronica, R., Filippi, V., Vera, M., Volpicelli, L., Candy, M., Alban, R., Di Bari, S., Gavaruzzi, F., Casali, E., Carli, M. S., Zingaropoli, A. M., Perri, V., Santinelli, L., Pinacchio, C., Nijhawan, P., Miele, C. M., Innocenti, P. G., and Mengoni, F.

Subjects
Male, covid-19, mortality, sars-cov-2, thrombosis, Coronary Artery Disease, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, law.invention, Coronary artery disease, 0302 clinical medicine, law, 80 and over, Coronary Artery Disease/epidemiology, Odds Ratio, SARS-cov-2, 030212 general & internal medicine, Prospective Studies, Aged, 80 and over, Thromboembolism/epidemiology, biology, Hazard ratio, Middle Aged, Mortality/trends, Intensive care unit, Thrombosis, Venous thrombosis, Intensive Care Units, C-Reactive Protein, Emergency Medicine, Cardiology, COVID-19/complications, Female, medicine.medical_specialty, Fibrin Fibrinogen Degradation Products/analysis, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, C-Reactive Protein/analysis, Internal medicine, Thromboembolism, Internal Medicine, medicine, Humans, Mortality, Aged, Proportional Hazards Models, Intensive Care Units/organization & administration, business.industry, C-reactive protein, COVID-19, Odds ratio, medicine.disease, Im - Original, Logistic Models, Heart failure, biology.protein, business
Abstract

Background Patients with coronavirus disease 2019 (Covid-19) may experience venous thrombosis while data regarding arterial thrombosis are sparse. Methods Prospective multicenter study in 5 hospitals including 373 patients with Covid-19-related pneumonia. Demographic data, laboratory findings including coagulation tests and comorbidities were reported. During the follow-up any arterial or venous thrombotic events and death were registered. Results Among 373 patients, 75 (20%) had a thrombotic event and 75 (20%) died. Thrombotic events included 41 venous thromboembolism and 34 arterial thrombosis. Age, cardiovascular disease, intensive care unit treatment, white blood cells, D-dimer, albumin and troponin blood levels were associated with thrombotic events. In a multivariable regression logistic model, intensive care unit treatment (Odds Ratio [OR]: 6.0; 95% Confidence Interval [CI] 2.8–12.6; p p = 0.022); and albumin levels (OR: 0.49; 95% CI 0.28–0.87; p = 0.014) were associated with ischemic events. Age, sex, chronic obstructive pulmonary disease, diabetes, heart failure, coronary heart disease, intensive care unit treatment, in-hospital thrombotic events, D-dimer, C-reactive protein, troponin, and albumin levels were associated with mortality. A multivariable Cox regression analysis showed that in-hospital thrombotic events (hazard ratio [HR]: 2.72; 95% CI 1.59–4.65; p p = 0.001), and albumin (HR: 0.447; 95% CI 0.277–0.723; p = 0.001) predicted morality. Conclusions Covid-19 patients experience an equipollent rate of venous and arterial thrombotic events, that are associated with poor survival. Early identification and appropriate treatment of Covid-19 patients at risk of thrombosis may improve prognosis.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results